Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6311653 | 0.80 | HRH3 (0.37) | PIK3CD | |
| SCHEMBL6317942 | 0.79 | KMT2A (0.38) | PIK3CDKDM4EADRA2AADORA2AHTT | |
| SCHEMBL6319337 | 0.77 | CSNK1E (0.35) | PIK3CDKDM4EADRA2AADORA2AHTT | |
| SCHEMBL6320019 | 0.75 | HRH4 (0.34) | PIK3CDKDM4EADRA2AADORA2AHTT | |
| SCHEMBL6311937 | 0.75 | PIK3CD (0.33) | PIK3CDKDM4EHSD17B10 | |
| SCHEMBL6311792 | 0.74 | AKT1 (0.40) | KDM4E | |
| SCHEMBL6654557 | 0.74 | CHRM4 (0.37) | KDM4EHSD17B10 | |
| SCHEMBL6319490 | 0.72 | ALDH1A1 (0.47) | KDM4EHTTHSD17B10 | |
| SCHEMBL6310367 | 0.72 | HTT (0.43) | PIK3CDKDM4EADRA2AADORA2AHTT | |
| SCHEMBL6310382 | 0.71 | CKS1B (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113397-A1 | Imidazo[1,2-a]pyridine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1479681-A1 | IMIDAZO(1,2-a)PYRIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113397-A1 | Imidazo[1,2-a]pyridine derivative | MANBA, MAN2B1, ERG28 | PIK3CD 2813/4885KDM4E 3360/4885ADRA2A 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.